Gloucester Pharmaceuticals Inc - 02142 Cambridge, MA

Business Name: Gloucester Pharmaceuticals Inc
Categorized In:
Address: 1 Broadway Floor 14, Cambridge, MA 02142
Phone Number: (617) 583-1300
Contact Person: Alan Colowick
Website Address: celgene.com
NAICS Code: 325412
SIC Code: 2834
Business Type: B2B & B2C
Founding Year: 2010
Employee #: 1 to 4
Location Type: Single Location
Annual Revenue ($): $500.000 to $999.999
Share This Business:
Similar Businesses: Il Pharma Inc - Cambridge, MA 02142
Newco Ls13 - Cambridge, MA 02142
Sanofi Us Services Inc - Cambridge, MA 02142
Shape Pharmaceuticals Inc - Cambridge, MA 02142
Verastem Inc - Cambridge, MA 02142
Targanta Therapeutics Corporation - Cambridge, MA 02142
Edimer Pharmaceuticals - Cambridge, MA 02142
Eleven Biotherapeutics - Cambridge, MA 02142
Constellation Pharmaceuticals - Cambridge, MA 02142
Millennium Pharmaceuticals - Cambridge, MA 02142
Aegerion Pharmaceuticals Inc - Cambridge, MA 02142
Via Cord LLC - Cambridge, MA 02142
Lipomed Inc - Cambridge, MA 02142
Ironwood Pharmaceuticals Inc - Cambridge, MA 02142
Momenta Pharmaceuticals Inc - Cambridge, MA 02142
Alnylam Pharmaceuticals Inc - Cambridge, MA 02142
Sarepta Therapeutics Inc - Cambridge, MA 02142
Zalicus Inc - Cambridge, MA 02142
Clarus Ventures LLC - Cambridge, MA 02142
Akanas Therapeutics Inc - Cambridge, MA 02142

Gloucester Pharmaceuticals Inc provides professional from its single location at the coordinates 42.362362,-71.083313.

The company offers BOTH variables under the SIC code 2834 and NAICS code 325412, while making an annual revenue of $500.000 to $999.999 and hiring a total of 1 to 4 employees.

Founded in 2010, the company can now be visited at 1 Broadway Floor 14, Cambridge, Massachusetts 02142 or contacted through representative Alan Colowick at (617) 583-1300.

For frequently asked questions and further inquiries about professional , get to know more about Gloucester Pharmaceuticals Inc through its company website at celgene.com. Engage with this business on its social media platforms through on Twitter and on Facebook.